Dylan Tokar / wsj - The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Back to Top / Sunday, October 26, 2025, 5:20 pm / permalink 15427 / 2 stories in 4 months
Eli Lilly to acquire Orna Therapeutics in a $2.4B biotech deal / 25 days
IVFmicro secures £3.5M to boost IVF treatment technology / 2 months
Sofinnova Partners Closes €650M Biopharma & MedTech Fund / 3 months
Adaptam Therapeutics secures €3M for cancer immunotherapy research / 4 months
UK biotech Nuclera secures Series C funding for advanced protein research / 7 wks
Amgen acquires Oxford’s Dark Blue Therapeutics in major biotech deal / 1 month
Gilead to acquire Arcellx for $7.8 billion in cash deal / 11 days
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.